Moderna (MRNA) Gross Profit (2020 - 2026)

Moderna (MRNA) has 7 years of Gross Profit data on file, last reported at -$566.0 million in Q1 2026.

• On a quarterly basis, Gross Profit fell 3244.44% year-over-year to -$566.0 million in Q1 2026; TTM through Mar 2026 was $492.0 million, a 71.38% decrease from a year earlier, with the FY2025 full-year figure at $1.1 billion, down 39.28% from the prior year.
• Gross Profit for Q1 2026 stood at -$566.0 million, down from $226.0 million in the prior quarter.
• Over the last five years, Gross Profit for MRNA reached as high as $5.0 billion in Q1 2022 and fell as low as -$566.0 million in Q1 2026.
• Historically, Gross Profit has averaged $1.2 billion across 5 years, with a median of $227.0 million in 2024.
• Across the five-year window, Gross Profit soared 428.78% in 2024 and slumped 3244.44% in 2026, its largest moves.
• Year by year, Gross Profit stood at $4.7 billion in 2022, then slumped by 59.82% to $1.9 billion in 2023, then slumped by 87.94% to $227.0 million in 2024, then fell by 0.44% to $226.0 million in 2025, then slumped by 350.44% to -$566.0 million in 2026.
• Per Business Quant data, the three most recent Gross Profit figures were -$566.0 million in Q1 2026, $226.0 million in Q4 2025, and $809.0 million in Q3 2025.